1,721,189 research outputs found
Integrating medical knowledge to improve science with a novel, straightforward attitude: the bio-integrative medicine
Full text link[no abstract available
La sindrome da stanchezza cronica ( chronic fatigue syndrome: implicazioni medico legali
No full text
Hepatitis C virus, mixed cryoglobulinemia and non-Hodgkin’s lymphoma
No full textThere is increasing evidence from recent studies that a
large number of diseases are related to infections. In the
field of haematology, many malignant disorders are now
related to some infectious agents, such as Epstein-Barr
virus (EBV) in Burkitt's lymphoma, human T lymphocyte
virus I (HTLV-I) in T-cell leukaemia-lymphoma,
Helicobacter pylori in gastric B-cell lymphoma, human
herpes virus (HHV-6, -7, -8) in Kaposi's sarcoma and
Castelman's disease and, perhaps, parvovirus B19 in pure
red cell aplasia. However, all these infectious agents are
widespread in the general population, but only a very small
fraction of infected patients develop the neoplastic disease,
indicating the crucial role of some, at present unknown,
underlying genetic factors.
An association between HCV infection and B-cell
lymphoma has been demonstrated in several geographical
areas. Although controversy remains, a pathogenetic
linkage between HCV and NHL is strongly suggested by
molecular and epidemiological evidence. However, despite
this evidence, the pathogenetic mechanisms underlying
HCV-associated lymphomas are still unknown. HCV-related
lymphomas could, therefore, represent an important model
for analysing virus–induced lymphomas in humans.
It has not been elucidated whether HCV exerts its
oncogenic effect through an indirect mechanism or whether
it uses other pathways directly. It can be said that in most
cases the viral infection does not have a significant impact
on either response to chemotherapy or survival of
lymphoma patients. Chemotherapy is relatively safe and
treatment regimes do not usually need to be interrupted.
Since the treatment of HCV infection can lead to
regression not only of chromosomal and molecular
abnormalities, but even of clinically evident low-grade
NHL118.119, new therapeutic strategies (pegylated interferons
plus ribavirin), currently recognised as the gold standard
for HCV antiviral therapy and able to eradicate HCV in a
high percentage of treated subjects (from 60 to 90% of
complete responders on the basis of HCV genotype: 1 vs.
non-1) are likely to drastically reduce the number of HCV
infected patients and, consequently, the number of HCVrelated
NHL
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HUMAN HERPESVIRUS-8 RELATED BODY-CAVITY-BASED LYMPHOMA
No full text3° Incontro scientifico Virus e Tumori Solidid. Ferrara 23 Marzo 2012.
No full textL’ iniziativa desidera in prima istanza verificare
lo stato dell’arte nel settore della oncologia
virale con specifico riferimento a virus
potenzialmente oncogeni trovati associati a
tumori solidi umani. In due precedenti incontri,
con il congresso di Pavia “Virus e Tumori Solidi”
del 20-21 Ottobre 2011, e con il meeting di
Aviano (PN) del 19 Gennaio 2011 sono state
poste le basi culturali per affrontare in maniera
multidisciplinare un argomento di forte attualità
ed impatto nel panorama sia scientifico che
sanitario.
Il terzo incontro che si svolge oggi a Ferrara, 23
Marzo 2012, ha come finalità un’ulteriore
disamina del tema e la proposizione di specifici
argomenti che potranno diventare progetti di
ricerca da presentare alle Agenzie finanziatrici
sia pubbliche che private. Il gruppo di ricercatori
del settore sono in grado di affrontare sia gli
argomenti di base, relativi ai processi biologici,
che le applicazioni cliniche, tipiche delle fasi di
diagnosi e cura dei tumori solidi. Inoltre, durante
il meeting scientifico si metteranno a confronto
diversi know-how relativi a tecnologie,
metodiche e protocolli standardizzati sia per il
laboratorio di ricerca che per la pratica clinica
con l’intento di condividere qualità e
riproducibilità dei dati
NEW ENTITIES IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA: HIV-POSITIVE AND ELDERLY PATIENTS
No full textThe hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and, according to the WHO report, the fourth commonest cause of death. The incidence of HCC has been rising in developed western countries in the last two decades, along with the emergence of hepatitis C virus infection and to the rise of immigration rates from HBV-endemic countries. In addition, even though the incidence of HCC reaches its highest peak among persons over 65 years, an increased incidence among younger individuals has been noted in the last two decades both in USA and Europe. In the last decades two kinds of HCC patients are more interesting, for clinical characteristics, than typical patients with HCC: elderly and HIV-positive patients. In fact due to the increase of the life expectancy in many countries, HCC represents a new challenge in this particular setting of patients
AIDS-associated non-Hodgkin's lymphomas in Italy: intravenous drug abusers versus homosexual men
No full text- …
